Lincoln Pharma ... the next mid-cap pharma in the making ...?

Very impressive management commentary post muted results.

30.05.2023 Zee (link)

  • FY26 target: 750 cr. revenues
  • Have started getting approval in Francophone Africa from Q4FY23 (started efforts 3 years ago). Launched products in 12 countries, have seen very good results in Q1FY24 so far
  • Regulated markets: exports started in Q3FY23 to Canada and expect $2-3mn from Canada in FY24. Currently in product identification phase in Australian market
  • Cephalosporin: Injectable lines have started and trial batches are ongoing. Last stage of expansion is getting over in next 1-1.5 months which will give 20% additional capacity and reduce capacity utilization from current 85-90% levels to 70% (thereby giving 20% extra growth)
  • Capex: 15-18 cr. for FY24 (either new lines or an additional facility). Looking to setup solar plant to reduce energy costs

Disclosure: Invested (position size here, no transactions in last-30 days)

11 Likes